Preemptive Therapy for Cryptococcal Meningitis: A Valid Strategy for Latin America?
AbstractAIDS-related cryptococcal meningitis continues to cause a substantial burden of death in low and middle income countries. Better diagnostics allow detection of cryptococcosis in the asymptomatic phase and using these technologies to screen at-risk persons would likely reduce mortality. The World Health Organization recommends cryptococcal antigen screening among populations with a prevalence of cryptococcal antigenaemia (CRAG) > 3%. There is scarce data about CRAG prevalence in Latin America. Four studies (only one published as a full text) showed asymptomatic CRAG prevalence between 2.7% and 6.2% in several sub-sets of HIV-infected patients. The CRAG lateral flow assay (LFA) has several advantages over other techniques for actual implementation of a screening program. Although more studies are necessary to confirm available data, implementation of the CRAG screening strategy seems to be opportune in Latin America. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Vidal, J.E. Preemptive Therapy for Cryptococcal Meningitis: A Valid Strategy for Latin America? J. Fungi 2016, 2, 14.
Vidal JE. Preemptive Therapy for Cryptococcal Meningitis: A Valid Strategy for Latin America? Journal of Fungi. 2016; 2(2):14.Chicago/Turabian Style
Vidal, José E. 2016. "Preemptive Therapy for Cryptococcal Meningitis: A Valid Strategy for Latin America?" J. Fungi 2, no. 2: 14.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.